Close Menu

NEW YORK – The US Centers for Medicare and Medicaid Services released a draft decision memo on Friday describing criteria for the coverage of current and future blood-based colorectal cancer screening tests.

The memo, which is currently open for public comment, has implications for a number of companies developing circulating tumor DNA and epigenomic tests in the space, and at least one firm currently marketing a blood-based assay, Epigenomics' Epi proColon.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.